-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

655.P1.27 655. Multiple Myeloma: Cellular Therapies: Poster I

Symposia: Multiple Myeloma: Cellular Therapies Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)

Amber Feng, MD1*, Taewoong Choi, MD2, Jian Wu, MD, PhD2*, Xiaobei Wang, PhD2*, Tanya Bellavia, PA-C2*, Daniel Schrum, PharmD2*, Erin Eberwein, PharmD2*, Sikai Cheng, BS1*, Jonathan Huggins, MD1*, Patrick Tam, MD1*, Suzanne Kirby, MD, PhD2, Cristina Gasparetto, MD3*, Cristiana Costa Chase, DO2, Gwynn D. Long, MD3*, Krista Rowe-Nichols, RN2* and Yubin Kang, MD3

1Duke University Hospital, Durham, NC
2Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC
3Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

Noffar Bar, MD1, Roberto Mina2*, Anne K. Mylin3*, Hisayuki Yokoyama4*, Hila Magen5*, Winfried Alsdorf6*, Monique C. Minnema7, Leyla O. Shune, MD8, Iris Isufi, MD9, Simon J Harrison, MBBS, PhD10,11,12, Urvi A. Shah, MD13, André De Champlain14*, Katharine S. Gries15*, Diana Chen16*, Quanlin Li17*, Tzu-Min Yeh18*, Ana Slaughter19*, Carolina Lonardi20*, Nina Benachour21*, Arnab Ghosh22*, William Deraedt23*, Martin Vogel24*, Nikoletta Lendvai25*, Nitin Patel26*, Octavio Costa Filho26*, Erika Florendo26*, Lionel Karlin27* and Katja C. Weisel, MD6

1Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
2Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
3Department of Hematology, Rigshospitalet, Copenhagen, Denmark
4Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
5Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, ISR
6University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
8Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Westwood, KS
9Division of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
10Royal Melbourne Hospital, Melbourne, Australia
11Peter MacCallum Cancer Centre, Melbourne, Australia
12Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
13Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
14Janssen Global Services, LLC, Horsham, PA
15Janssen Research & Development, LLC, Raritan, NJ
16Janssen Research & Development, Shanghai, China
17Janssen Research & Development, Apex, NC
18Janssen Research and Development, Raritan, NJ
19Cilag GmbH International, Zug, Switzerland
20Janssen, Buenos Aires, Argentina
21Janssen Research & Development, Beerse, Belgium
22Janssen Research & Development, Raritan, NJ
23Janssen Research and Development, Beerse, Belgium
24Janssen Research & Development, Neuss, Germany
25Oncology Clinical Development, Johnson and Johnson Innovative Medicine, Bridgewater, NJ
26Legend Biotech USA Inc., Somerset, NJ
27Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Nico Gagelmann, MD1*, Friedrich Stölzel2*, Roland Fenk, MD, PhD3*, Tobias A.W. Holderried, MD4*, Fabian Mueller, MD5*, Natalia Tovar, MD6*, Aina Oliver-Caldés, MD, PhD7*, Kristin Rathje8*, Vladan Vucinic, MD9*, Soraya Kharboutli, MD5*, Ben-Niklas Bärmann10,11*, Francis A. Ayuk, M.D.12*, Uwe Platzbecker, MD13, Anca Maria Albici14*, Natalie Schub15*, Friederike Schmitz16*, Cyrus Khandanpour17, Marcel Teichert18*, Barbara Jeker19*, Nicolaus Kroeger12,20, Bastian von Tresckow21, Carlos Fernandez de Larrea, MD22, Thomas Pabst23 and Maximilian Merz, MD13

1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
2Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel, Germany
3Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
4Universitaetsklinikum Bonn (UKB), Bonn, Germany
5Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany
6Hospital Clinic de Barcelona, IDIBAPS., Barcelona, Spain
7Hospital Universitari Son Espases, IdISBa, Palma de Mallorca, ESP
8Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, AL, Germany
9Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Saxony, Germany
10DüSseldorf University Hospital, DüSseldorf, ERI
11Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany
12Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
13Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
14Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
15Department of Internal Medicine II, Division of Stem Cell Transplantation and Immunotherapy, UKSH Campus, Kiel, Germany
16Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany
17University Cancer Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
18Department of Hematology and Stem Cell Transplantation, Department of Hematology and Oncology, University Hospital Essen, Essen, Germany, Essen, Germany
19Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
20Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, DEU
21Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
22Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
23Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

Fnu Amisha, MD1, Ziad Abuhelwa, MD1, Wenyi Fan, MSPH2*, Doris K. Hansen, MD3*, Omar Castaneda, MD3, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP3, Hien Liu, MD3, Frederick Locke, MD4, Taiga Nishihori, MD4, Ariel Grajales-Cruz, MD5, Brandon Blue5, Kenneth H. Shain, MD, PhD5, Melissa Alsina, MD4 and Rachid Baz, MD4

1Department of Hematology and Oncology, USF Morsani/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4Moffitt Cancer Center, Tampa, FL
5Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Rafael Fonseca, MD1, Joris Diels2*, Francesca Ghilotti3*, João Mendes4*, Teresa Hernando5*, Seina Lee4*, Jordan M. Schecter6, Nikoletta Lendvai7*, Nitin Patel8*, Ana Triguero9*, Winfried Alsdorf10* and Margherita Ursi11*

1Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
2Janssen Pharmaceutica NV, Beerse, Belgium
3Janssen-Cilag SpA, Milano, Italy
4Janssen Global Services, LLC, Raritan, NJ
5Janssen-Cilag, Madrid, Spain
6Janssen Research and Development, LLC, Raritan, NJ
7Oncology Clinical Development, Johnson and Johnson Innovative Medicine, Bridgewater, NJ
8Legend Biotech USA Inc., Somerset, NJ
9Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain
10Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
11Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy, Bologna, Italy

Hitomi Hosoya, MD, PhD1, Alexandria Jensen2*, Vanna Hovanky, MS3*, Sylvester Homsy, MD4, Juancarlos E Cancilla5*, Sunita Patil5*, Vanessa E. Kennedy, MD1, Sushma Bharadwaj, MD1, Melody Smith, MD, MS6, Parveen Shiraz7*, Matthew J. Frank, MD, PhD8, Saurabh Dahiya, MD, FACP7*, Sally Arai, MD7, Wen-Kai Weng, MD, PhD1, Lori Muffly, MD6, Bita Sahaf7*, Crystal L. Mackall, MD9, David B. Miklos, MD, PhD1, Lekha Mikkilineni, MD, MA10 and Surbhi Sidana, MD6

1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
2Quantitative Sciences Unit, Stanford University, Stanford, CA
3Stanford University, Stanford, CA
4Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Brooklyn, Lebanon
5Cancer Correlative Science Unit, Stanford University, Palo Alto, CA
6Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
7Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
8Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University, Stanford, CA
9Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
10Division of Blood and Marrow Transplant and Cellular Therapy, Stanford University, Palo Alto, CA

Johannes Waldschmidt, MD1, David Fandrei, MSc2*, Vladan Vucinic, MD3*, Ralph Wäsch4, Axel Nogai, MD5*, Winfried Alsdorf6*, Annamaria Brioli, MD, PhD7,8*, Evgenii Shumilov9*, Fabian Mueller, MD10, Raphael Teipel, MD11*, Nico Gagelmann, MD12*, Monika Engelhardt, MD13, Jan Krönke, MD14, Julia Mersi, MD1*, Michael Hudecek, MD, PhD1*, Martin K. Kortüm15*, Uwe Platzbecker, MD2, Hermann Einsele, MD16, Max S. Topp1*, Leo Rasche, MD17,18* and Maximilian Merz, MD2

1Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
2Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
3Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Saxony, Germany
4Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
5Charité Medical University, Berlin, Germany
6University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Klinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany
8Department of Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany
9Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
10Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany
11Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany
12Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
13Department of Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
14Charité - Universitätsmedizin Berlin, Berlin, Germany
15Würzburg University Hospital, Wuerzburg, Germany
16Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
17Mildred-Scheel-Nachwuchszentrum, Wuerzburg, Germany
18Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany

Ahmad Iftikhar, MD1*, Hiba Arshad Shahani, MBBS2*, Mohammad Ebad Ur Rehman, MBBS2*, Muhammad Sheraz Hameed, MBBS3*, Syed Ali Raza Abidi, MBBS4*, Fathima Shehnaz Ayoobkhan, MD5, Rana Uzair Ahmad, MBBS6*, Afreen Quadri, MBBS7*, Muhammad Suhaib8*, Omar A Safdar1*, Faiz Anwer, MD9 and Muhammad Husnain, M.D.1

1University of Arizona, Tucson, AZ
2Rawalpindi Medical University, Rawalpindi, Pakistan
3Rawalpindi Medical University, Rawalpindi, PAK
4D.G. Khan Medical College, Dera Ghazi Khan, Pakistan
5Trinity Health Oakland, Pontiac, MI
6King Edward Medical University, Lahore, Pakistan
7Dr. V. R.K. Women’s Medical College, Aziznagar, India
8Allama Iqbal Medical College, Lahore, Pakistan
9Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Alma Habib, MD1,2, Nausheen Ahmed, MD1,3, Abdullah Mohammad Khan, MD, MBBS1,2, Darryl Chang, MD1,4, Barry Paul, MD, MS1,4, Hira Shaikh, MD1,5, Christopher Strouse, MD1,5, Emily Struble, DNP1,5*, Andrew Vegel, MD1,5*, James A Davis, PharmD1,6*, Kimberly M Green, DO1,6*, Hamza Sloan Hashmi, MD6,7,8*, Zahra Mahmoudjafari, PharmD1,9*, Muhammad Umair Mushtaq1,9, Joseph P. McGuirk, DO10, Al-Ola Abdallah, MD1,9, Shebli Atrash, MD, MS1,4 and Reed Friend, MD1,4

1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
2Division of Hematology, The Ohio State University, Columbus, OH
3University of Kansas Cancer Center, Kansas City, KS
4Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
5Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA
6Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering, New York, NY
8US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, NY
9Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
10Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Ctr., Westwood, KS

*signifies non-member of ASH